Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
OBJECTIVE
In this study, we aimed to investigate the activities of paraoxonase-1 (PON1) and nitric oxide synthase (NOS) and the levels of asymmetric dimethylarginine (ADMA), nitric oxide (NO), oxidized low-density lipoprotein (oxLDL), ceruloplasmin (CP), thiobarbituric acid-reactive substances (TBARS), malondialdehyde (MDA), 4-hydroxynonenal (HNE) and lipids in serum of patients with end-stage renal disease (ESRD) having continuous ambulatory peritoneal dialysis (CAPD) treatment and controls living in the Antalya region, Turkey.


METHODS
Fifty-three patients with ESRD were enrolled in this study and were treated by CAPD. As the control group (n=32), subjects with normal renal function were included.


RESULTS
Serum PON1 activity and high-density lipoprotein-cholesterol (HDL-C) levels were decreased in ESRD patients whereas ADMA, NO, oxLDL, CP, TBARS, MDA and HNE levels and NOS activity were increased with regard to control group. In CAPD patients, ADMA positively correlated with NO, CP, oxLDL, TBARS and MDA levels whereas negatively correlated with PON1 activity. On multiple logistic regression analysis, risk factors associated with ESRD included CP, TBARS, triglycerides (TG) and very low-density lipoprotein-cholesterol (VLDL-C) levels.


CONCLUSIONS
Our data have demonstrated that ESRD patients on CAPD treatment exhibit increased lipid peroxidation reactions and decreased antioxidant protection. The assay of serum HNE and MDA may be useful to evaluate the individual accumulation of these toxic aldehydes to test the efficiency of new dialysis strategies in removing them.
Göçmen
Ayşe Yeşim
AY
Department of Biochemistry, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey.
Sahin
Emel
E
Koçak
Hüseyin
H
Tuncer
Murat
M
Gümüşlü
Saadet
S
D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D043303:Aryldialkylphosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D015227:Lipid Peroxidation; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000097:blood*; D019001:Nitric Oxide Synthase / Q000097:blood*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D012016:Reference Values; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D015415:Biomarkers; D008055:Lipids; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; C487735:dimethylarginine; C099252:oxidized low density lipoprotein; D009569:Nitric Oxide; D001120:Arginine; D019001:Nitric Oxide Synthase; D043303:Aryldialkylphosphatase